ArticleHealth and quality of life outcomes2017
Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.
Massimo Breccia et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.